Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.

Leukemia - 1 Apr 2006

Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F, Peschel C, Duyster J

Abstract excerpt

Mutations in the Bcr-Abl kinase domain are a frequent cause of imatinib resistance in patients with advanced CML or Ph+ ALL. The impact of these mutations on the overall oncogenic potential of Bcr-Abl and on the clinical course of the disease in the absence of imatinib is presently unclear. In this study, we analyzed the effects of the Bcr-Abl P-loop mutation Y253H and the highly imatinib resistant T315I mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cell Transformation, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Gene Transfer Techniques

Share to Imatinib Mesylate

Share to Neoplasm Transplantation

Share to NIH 3T3 Cells

Share to Retroviridae

Source

Identifiers

PMID: 16482207
DOI: 10.1038/sj.leu.2404151

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.PMID 16482207Read ↗

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.Semantic proximity Read ↗

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.Semantic proximity Read ↗

The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.Semantic proximity Read ↗

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.Semantic proximity Read ↗

Tyrosine Kinase Activity and Transformation Potency of <i>bcr-abl</i> Oncogene ProductsSemantic proximity Read ↗

Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.Semantic proximity Read ↗

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.Semantic proximity Read ↗

Resistance to Imatinib of Bcr/Abl P190 Lymphoblastic Leukemia CellsSemantic proximity Read ↗

SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.Semantic proximity Read ↗

Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.Semantic proximity Read ↗

The P190, P210, and P230 Forms of the <i>BCR/ABL</i> Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic ActivitySemantic proximity Read ↗

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.